Follow us on Twitter
twitter icon@FreshPatents


Histocompatibility patents

      

This page is updated frequently with new Histocompatibility-related patent applications.




 Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides patent thumbnailCleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides
In one aspect, the disclosure relates to major histocompatibility complex (mhc) molecules comprising a ligand in the peptide binding groove of the mhc molecule, whereby the ligand comprises an azobenzene (abc), and at least two amino acid residues separated by the azo-group of the abc, and wherein the amino acid residues are positioned to interact with the peptide binding groove of the mhc molecule. The disclosure also relates, among others, to means and methods for producing and using such mhc molecules, and the ligands therefor..
Technische Universität München


 Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers patent thumbnailNovel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Medicament for use in a  inducing or extending a cellular cytotoxic immune response patent thumbnailMedicament for use in a inducing or extending a cellular cytotoxic immune response
The present invention relates to a medicament for use in a method of extending a cellular cytotoxic immune response against an antigen-comprising protein, the method comprising the step of: i) administering to a patient having t cells activated against an antigen a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and an adjuvant which supports a th-1-mediated response, wherein the peptide is derived from the antigen-comprising protein, thereby re-activating the activated t cell, wherein the peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell of step i) is administered in a time frame of from 0 h to 14 days after the t cells were activated against an antigen.. .
Bundesrepublik Deutschland Ietzvertreten Durch Das Robert Koch-institut Vertreten Durch Seinen Präsi


 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers patent thumbnailNovel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 A medicament for use in a  inducing or extending a cellular cytotoxic immune response patent thumbnailA medicament for use in a inducing or extending a cellular cytotoxic immune response
The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a t cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (il-2cx), (e) a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating the t cell activated in step i), wherein the re-activator of step ii) is administered in a time frame of from 0 h to 14 days after the administration of the delivery system of step i).. .
Bundesrepublik Deutschland Ietztvertreten Durch Da S Robert Koch-institut Vertreten Durch Seinen Prä


 Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications patent thumbnailTransgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted h2 class i gene, a disrupted h2 class ii gene, a functional hla class i transgene, and a functional hla class ii transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both h2 class i and class ii molecules, wherein the transgenic mouse comprises a functional hla class i transgene and a functional hla class ii transgene.
Institut Pasteur


 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers patent thumbnailNovel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers patent thumbnailNovel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers patent thumbnailNovel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


 Method for identifying novel minor histocompatibility antigens patent thumbnailMethod for identifying novel minor histocompatibility antigens
A novel method for human minor histocompatibility antigen (miha) discovery, novel mihas identified using this method, as well as uses of the novel mihas, are described. One of the features of the novel method is the inclusion of personalized translated transcriptome and/or exome in the database used for peptide identification by mass spectroscopy (ms).
UniversitÉ De MontrÉal


Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnology Gmbh

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Peptide sequences and compositions

Wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (mhc) allele, and wherein the polypeptide is not a complete influenza virus protein.. .

Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen

The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a muc1 tumor antigen independently of an major histocompatibility complex (mhc). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a t cell receptor.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma.
Immatics Biotechnologies Gmbh



Histocompatibility topics:
  • Histocompatibility
  • Compatibility
  • Major Histocompatibility Complex
  • Immune Response
  • Specificity
  • Antibodies
  • Recombinant
  • Polypeptide
  • Stimulator
  • Immunostimulator
  • Therapeutics
  • Monoclonal Antibody
  • Immunotherapy
  • Monoclonal
  • Nucleic Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Histocompatibility for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Histocompatibility with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3123

    file did exist - 3101

    0 - 1 - 51